Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Heinrich, Eileen L ^a   Lee, Wendy ^a   Lu, Jianming ^a   Lowy, Andrew M ^b   Kim, Joseph ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CXCL12; CXCR4; CXCR7; MAPK; Pancreatic cancer

Indexed keywords

BETA ARRESTIN 2; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; BETA ARRESTIN; CHEMOKINE RECEPTOR CXCR; CXCR4 PROTEIN, HUMAN; CXCR7 PROTEIN, HUMAN; FORMALDEHYDE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PARAFFIN; RAS PROTEIN; RETINA S ANTIGEN;

ARTICLE; ASSAY; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; DRUG EFFECT; ENZYMOLOGY; GENE SILENCING; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; TISSUE FIXATION; TUMOR CELL LINE;

ARRESTINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FORMALDEHYDE; GENE KNOCKDOWN TECHNIQUES; HUMANS; PANCREATIC NEOPLASMS; PARAFFIN EMBEDDING; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTORS, CXCR; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TISSUE FIXATION;

EID: 84859136834     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-68     Document Type: Article

References (42)

1. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550. 10.1038/nrc1388, 15229479.
2. Ratajczak M, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 2006, 20:1915-1924. 10.1038/sj.leu.2404357, 16900209.
3. Corcione A, Ottonello L, Tortolina G, Facchetti P, Airoldi I, Guglielmino R, Dadati P, Truini M, Sozzani S, Dallegri F, Pistola V. Stromal cell-derived factor-1 as a chemoattractant for follicular center lymphoma B cells. J Natl Cancer Inst 2000, 92:628-635. 10.1093/jnci/92.8.628, 10772680.
4. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000, 6:3530-3535.
5. Scotton C, Wilson J, Scott K, Stamp G, Wilbanks G, Fricker S, Bridger G, Balkwill F. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002, 62:5930-5938.
6. Saur D, Seidler B, Schneider G, Algül H, Beck R, Senekowitsch-Schmidtke R, Schwaiger M, Schmid R. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology 2005, 129:1237-1250. 10.1053/j.gastro.2005.06.056, 16230077.
7. Marchesi F, Monti P, Leone B, Zerbi A, Vecchi A, Piemonti L, Mantovani A, Allavena P. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004, 64:8420-8427. 10.1158/0008-5472.CAN-04-1343, 15548713.
8. Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K, Masui T, Fujimoto K, Tamamura H, Hiramatsu K, et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 2004, 3:29-37. 10.4161/cbt.3.1.547, 14749473.
9. Feng Y, Broder C, Kennedy P, Berger E. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877. 10.1126/science.272.5263.872, 8629022.
10. Endres M, Clapham P, Marsh M, Ahuja M, Turner J, McKnight A, Thomas J, Stoebenau-Haggarty B, Choe S, Vance P, et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996, 87:745-756. 10.1016/S0092-8674(00)81393-8, 8929542.
11. Bleul C, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer T. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382:829-833. 10.1038/382829a0, 8752280.
12. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier J, Arenzana-Seisdedos F, Schwartz O, Heard J, Clark-Lewis I, Legler D, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 385:833-835.
13. Rubin J, Kung A, Klein R, Chan J, Sun Y, Schmidt K, Kieran M, Luster A, S RA. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003, 100:13513-13518. 10.1073/pnas.2235846100, 263845, 14595012.
14. Zeelenberg I, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003, 63:3833-3839.
15. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan M, McClanahan T, Murphy E, Yuan W, Wagner S, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56. 10.1038/35065016, 11242036.
16. Balabanian K, Lagane B, Infantino S, Chow K, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005, 280:35760-35766. 10.1074/jbc.M508234200, 16107333.
17. Burns J, Summers B, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold M, Sunshine M, Littman D, Kuo C, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203:2201-2213. 10.1084/jem.20052144, 2118398, 16940167.
18. Miao Z, Luker K, Summers B, Berahovich R, Bhojani M, Rehemtulla A, Kleer C, Essner J, Nasevicius A, Luker G, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 2007, 104:15735-15740. 10.1073/pnas.0610444104, 1994579, 17898181.
19. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff R, Li M, Woehl B, Leung H, Groom J, Batten M, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci USA 2007, 104:14759-14764. 10.1073/pnas.0702229104, 1976222, 17804806.
20. Wang Y, Li G, Stanco A, Long J, Crawford D, Potter G, Pleasure S, Behrens T. JL R: CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron 2011, 69:61-76. 10.1016/j.neuron.2010.12.005, 3025760, 21220099.
21. Infantino S, Moepps B, Thelen M. Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. J Immunol 2006, 176:2197-2207.
22. Hattermann K, Held-Feindt J, Lucius R, Müerköster S, Penfold M, Schall T, Mentlein R. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 2010, 70:3299-3308. 10.1158/0008-5472.CAN-09-3642, 20388803.
23. Shen X, Jackson D, Artinyan A, Thomas R, Lowy A, Kim J. Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways. Pancreas 2010, 39:81-87. 10.1097/MPA.0b013e3181bb2ab7, 19820417.
24. Thomas R, Kim J, Revelo-Penafiel M, Angel R, Lowy A. The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut 2008, 57:1555-1560. 10.1136/gut.2007.143941, 18664506.
25. Rajagopal S, Rajagopal K, Lefkowitz R. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010, 9:373-386. 10.1038/nrd3024, 2902265, 20431569.
26. Pohl G, Ho C, Kurman R, Bristow R, Wang T, Shih I. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005, 65:1994-2000. 10.1158/0008-5472.CAN-04-3625, 15753399.
27. Shen X, Mailey B, Ellenhorn J, Chu P, Lowy A, Kim J. CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. J Gastrointest Surg 2009, 13:1955-1962. 10.1007/s11605-009-1002-8, 19756884.
28. Xu H, Wu Q, Dang S, Jin M, Xu J, Cheng Y, Pan M, Wu Y, Zhang C, Zhang Y. Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS One 2011, 6:e27399. 10.1371/journal.pone.0027399, 3236747, 22180778.
29. Weinstein I, Joe A. Oncogene addiction. Cancer Res 2008, 68:3077-3080.
30. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242. 10.1146/annurev.immunol.18.1.217, 10837058.
31. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127. 10.1016/S1074-7613(00)80165-X, 10714678.
32. Balkwill F. Chemokine biology in cancer. Semin Immunol 2003, 15:49-55.
33. Deramaudt T, Rustgi A. Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 2005, 1756:97-101.
34. Hruban R, Wilentz R, Kern S. Genetic progression in the pancreatic ducts. Am J Pathol 2000, 156:1821-1825. 10.1016/S0002-9440(10)65054-7, 1850064, 10854204.
35. Kato K, Ueoka Y, Kato K, Tamura T, Nishida J, Wake N. Oncogenic Ras modulates epidermal growth factor responsiveness in endometrial carcinomas. Eur J Cancer 1998, 34:737-744. 10.1016/S0959-8049(97)10124-1, 9713283.
36. Watanabe M, Nobuta A, Tanaka J, Asaka M. An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int J Cancer 1996, 67:264-268. 10.1002/(SICI)1097-0215(19960717)67:2<264::AID-IJC18>3.0.CO;2-B, 8760597.
37. DeFea KA. Beta-arrestins as regulators of signal termination and transduction: how do they determine what to scaffold?. Cell Signal 2011, 23:621-629. 10.1016/j.cellsig.2010.10.004, 20946952.
38. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010, 9:373-386. 10.1038/nrd3024, 2902265, 20431569.
39. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz RJ. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci USA 2010, 107:628-632. 10.1073/pnas.0912852107, 2818968, 20018651.
40. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002, 527:255-262. 10.1016/S0014-5793(02)03143-5, 12220670.
41. Kalatskaya I, Berchiche Y, Gravel S, Limberg B, Rosenbaum J, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009, 75:1240-1247. 10.1124/mol.108.053389, 19255243.
42. De Clercq E. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem 2005, 5:805-824. 10.2174/1389557054867075, 16178723.